<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Boyer, David</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Intraocular Use of Anti-VEGF Antibody Fragment Improves Vision and Retinal Anatomy in DR</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-15</style></pages><abstract><style  face="normal" font="default" size="100%">Ranibizumab, an anti-VEGF antibody fragment that is designed for intraocular use in diabetic retinopathy (DR), led to rapid and sustained improvement in both vision and retinal anatomy, reduced progression of DR, and improved patient-reported function in the RISE and RIDE clinical trials.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>